| Bioactivity | Cyclo(RGDyC) TFA is a cyclic pentapeptide with anti-angiogenic abilities. Cyclo(RGDyC) TFA can be combined with liposome delivery systems for research on ocular neovascular diseases and cancer[1][2]. |
| Name | Cyclo(RGDyC) TFA |
| Sequence | cyclo(Arg-Gly-Asp-{d-Tyr}-Cys) |
| Shortening | cyclo(RGD-{d-Tyr}-C) |
| Formula | C24H34N8O8S.xC2HF3O2 |
| Molar Mass | 594.64 (free base) |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lu Y, et al. Aqueous synthesized near-infrared-emitting quantum dots for RGD-based in vivo active tumour targeting. Nanotechnology. 2013 Apr 5;24(13):135101. [2]. Tang M, et al. Photostable and Biocompatible Fluorescent Silicon Nanoparticles-Based Theranostic Probes for Simultaneous Imaging and Treatment of Ocular Neovascularization. Anal Chem. 2018 Jul 3;90(13):8188-8195. |
Cyclo(RGDyC) TFA
CAS: F: C24H34N8O8S.xC2HF3O2 W: 594.64 (free base)
Cyclo(RGDyC) TFA is a cyclic pentapeptide with anti-angiogenic abilities. Cyclo(RGDyC) TFA can be combined with liposome
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.